| Serial Number | 97929646 |
| Word Mark | HUMANIS |
| Filing Date | Wednesday, May 10, 2023 |
| Status | 600 - ABANDONED - INCOMPLETE RESPONSE |
| Status Date | Friday, October 4, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Systemic anti-infectives, namely, antiparasitic, antibacterial and antifungal pharmaceuticals; Musculo-skeletal system pharmaceutical products for the treatment of musculo-skeletal system diseases; Cardiovascular pharmaceuticals, namely, diuretics, lipid lowering agents, beta blocking agents, and calcium antagonists being calcium channel blockers; Pharmaceuticals for the prevention and treatment of disorders of the nervous system, namely, pharmaceuticals in the nature of analgesics, psychoanaleptics, and psycoleptics for the treatment of psychosis, anti-epileptics for the treatment of epilepsy, central nervous system drugs being drugs for the treatment of central nervous system disorders, anaesthetics, antiparkinson preparations for the treatment of parkinson's disease, namely, antiparkinson pharmaceuticals; Pharmaceuticals for the treatment of respiratory diseases and asthma; Pharmaceuticals for the treatment of hormonal disorders and the prevention of osteoporosis; Anti-diabetic pharmaceuticals; insulins; Pharmaceuticals for the treatment of Alimentary Tract and Metabolism; Pharmaceuticals for the treatment of bone diseases and joint diseases; Pharmaceuticals for the treatment of blood and blood forming organs; Pharmaceuticals for the treatment of viral and infectious diseases; Pharmaceuticals for use as antineoplastic agents, namely, pharmaceuticals for the treatment of cancer; Pharmaceuticals for the treatment of immune system related diseases and disorders; Pharmaceuticals for the treatment of sensory organs; Pharmaceuticals for the treatment of kidney diseases; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals for ophthalmological use |
| Pseudo Mark | HUMAN IS |
| Translation of Words in Mark | The wording "Humanis" has no meaning in a foreign language. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 8, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | HUMANIS SAGLIK ANONIM SIRKETI |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Istanbul 34100 TR |
| Event Date | Event Description |
| Saturday, May 13, 2023 | NEW APPLICATION ENTERED |
| Monday, February 5, 2024 | ASSIGNED TO EXAMINER |
| Thursday, June 8, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, February 9, 2024 | NON-FINAL ACTION WRITTEN |
| Friday, February 9, 2024 | NON-FINAL ACTION E-MAILED |
| Friday, February 9, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, May 9, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, May 9, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, May 9, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, June 7, 2024 | FINAL REFUSAL E-MAILED |
| Friday, June 7, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Friday, June 7, 2024 | FINAL REFUSAL WRITTEN |
| Thursday, August 29, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, August 29, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, August 29, 2024 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Monday, September 9, 2024 | ABANDONMENT - INCOMPLETE RESPONSE |
| Friday, October 4, 2024 | ABANDONMENT NOTICE E-MAILED - INCOMPLETE RESPONSE |